Physician profile
Sarah Lauren Chagnon
NPI 1770711269
$27,587.13
in general payments reported to CMS, 2019-2025
9 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Neurodevelopmental Disabilities (Psychiatry & Neurology) providers received nationally (typical 2025 total: $328).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $288 · 2021: $1,226 · 2022: $122 · 2023: $144 · 2024: $3,088 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $2,480 · Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,430.00 |
| Travel and Lodging | $2,480.32 |
| Food and Beverage | $1,455.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $13,254.73 | 2024-2025 | Daybue |
| Livanova USA, INC. | $12,251.58 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Biomarin Pharmaceutical INC. | $1,347.34 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $465.53 | 2023-2025 | Qelbree, Qelbree |
| Novartis Pharmaceuticals Corporation | $116.61 | 2019 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $93.62 | 2019 | |
| Genentech USA, INC. | $40.54 | 2019 | |
| Travere Therapeutics, INC. | $17.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Chagnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.